LumiraDx Limited (LMDX)
LumiraDx Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in London, GB. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $5.1M. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -176.5%. Its beta of 1.71 implies it has historically moved more than the broad market.
LumiraDx Limited is a prominent provider of point-of-care diagnostic solutions. Its core mission is to revolutionize community healthcare by equipping medical professionals with crucial diagnostic insights directly at the patient's side. The company develops and commercializes a sophisticated diagnostic platform, offering a diverse array of tests that deliver laboratory-grade performance directly at the point of care. With approximately 30 tests either commercially available or under development, their comprehensive portfolio addresses critical conditions such as infectious diseases, cardiovascular disorders, diabetes, and coagulation issues. Furthermore, they offer a full suite of COVID-19 testing solutions, adaptable for both laboratory environments and immediate point-of-need applications. These diagnostic tools are widely adopted by governments and healthcare institutions, deployed in diverse settings including traditional laboratories, urgent care clinics, physician's offices, pharmacies, schools, and workplaces. Their applications span screening, diagnosis, and monitoring for both general wellness and specific diseases. Established in 2014, the company's headquarters are located in London, United Kingdom.
LumiraDx Limited is most often compared with the following Healthcare names: